Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Shaker Investments LLC OH

Shaker Investments LLC OH lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 44,658 shares of the medical equipment provider’s stock after selling 145 shares during the quarter. Lantheus accounts for about 1.7% of Shaker Investments LLC OH’s portfolio, making the stock its 16th largest holding. Shaker Investments LLC OH owned about 0.06% of Lantheus worth $3,995,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares during the period. CWM LLC boosted its stake in Lantheus by 63.0% during the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock worth $82,000 after buying an additional 290 shares during the last quarter. UMB Bank n.a. grew its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Lantheus by 57.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider’s stock worth $139,000 after acquiring an additional 460 shares during the last quarter. Finally, Procyon Advisors LLC raised its holdings in shares of Lantheus by 16.0% during the 3rd quarter. Procyon Advisors LLC now owns 3,252 shares of the medical equipment provider’s stock worth $357,000 after acquiring an additional 449 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $86.91 on Tuesday. The business has a 50-day simple moving average of $92.02 and a 200-day simple moving average of $98.46. The company has a market cap of $6.04 billion, a PE ratio of 14.46 and a beta of 0.44. Lantheus Holdings, Inc. has a one year low of $54.69 and a one year high of $126.89.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial restated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.